Revelation Biosciences (NASDAQ:REVBW – Get Free Report) is projected to post its results before the market opens on Thursday, November 5th. Analysts expect Revelation Biosciences to announce earnings of ($6.16) per share for the quarter.
Revelation Biosciences Trading Down 31.1%
Revelation Biosciences stock opened at $0.00 on Wednesday. The stock has a fifty day moving average price of $0.01 and a 200 day moving average price of $0.01. Revelation Biosciences has a 52 week low of $0.00 and a 52 week high of $0.04.
About Revelation Biosciences
Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that harness the body’s innate immune system to prevent and treat disease. The company’s programs are based primarily on Gemini, its proprietary formulation of an innate immune modulator designed for administration through the nose.
Revelation’s product candidates are being investigated for potential use in respiratory and other infectious diseases, with research aimed at stimulating an early immune response in the nasal passages and airways.
Read More
- Five stocks we like better than Revelation Biosciences
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
